

# Joana Bicker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1197062/publications.pdf>

Version: 2024-02-01

31  
papers

905  
citations

706676

14  
h-index

536525

29  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1596  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future. Ageing Research Reviews, 2022, 77, 101612.	5.0	26
2	Is intranasal administration an opportunity for direct brain delivery of lacosamide?. European Journal of Pharmaceutical Sciences, 2021, 157, 105632.	1.9	9
3	A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration. International Journal of Pharmaceutics, 2021, 593, 120161.	2.6	15
4	Development and application of an HPLC-DAD technique for human plasma concentration monitoring of perampanel and lamotrigine in drug-resistant epileptic patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1162, 122491.	1.2	10
5	Novel Routes to Accessing the Brain: Intranasal Administration. , 2021, , 39-72.		0
6	HPLC method for the determination of antiepileptic drugs in human saliva and its application in therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2021, 197, 113961.	1.4	7
7	Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. Life Sciences, 2021, 275, 119342.	2.0	18
8	Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression. Pharmaceutics, 2021, 13, 1975.	2.0	12
9	Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation. Frontiers in Pharmacology, 2021, 12, 751321.	1.6	8
10	Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges. Life Sciences, 2020, 240, 117093.	2.0	12
11	Repairing blood-CNS barriers: Future therapeutic approaches for neuropsychiatric disorders. Pharmacological Research, 2020, 162, 105226.	3.1	3
12	Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. Pharmaceutics, 2020, 12, 943.	2.0	3
13	Cystic fibrosis: Physiopathology and the latest pharmacological treatments. Pharmacological Research, 2020, 162, 105267.	3.1	12
14	QbD-driven development of intranasal lipid nanoparticles for depression treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 106-120.	2.0	29
15	Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After Intranasal Administration. Pharmaceutical Research, 2020, 37, 74.	1.7	13
16	Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics. British Journal of Pharmacology, 2020, 177, 2215-2239.	2.7	46
17	Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2020, 181, 113109.	1.4	41
18	Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders. Current Pharmaceutical Design, 2020, 26, 594-619.	0.9	17

#	ARTICLE	IF	CITATIONS
19	Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. <i>Drug Discovery Today</i> , 2019, 24, 1911-1923.	3.2	23
20	Nose-to-brain delivery of levetiracetam after intranasal administration to mice. <i>International Journal of Pharmaceutics</i> , 2019, 564, 329-339.	2.6	40
21	ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches. <i>Pharmacological Research</i> , 2019, 144, 357-376.	3.1	49
22	Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review. <i>Analytica Chimica Acta</i> , 2019, 1076, 18-31.	2.6	24
23	In vitro assessment of the interactions of dopamine $\beta$ -hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 35-40.	1.9	9
24	Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma. <i>Bioanalysis</i> , 2018, 10, 541-557.	0.6	17
25	Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective. <i>Current Drug Metabolism</i> , 2018, 19, 1021-1041.	0.7	7
26	Screening of pharmacokinetic properties of fifty dihydropyrimidin(thi)one derivatives using a combo of in vitro and in silico assays. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, 334-346.	1.9	9
27	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1282-1291.	1.7	19
28	A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates. <i>International Journal of Pharmaceutics</i> , 2016, 501, 102-111.	2.6	41
29	Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: A review. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 87, 409-432.	2.0	222
30	Liquid chromatographic methods for the quantification of catecholamines and their metabolites in several biological samples: A review. <i>Analytica Chimica Acta</i> , 2013, 768, 12-34.	2.6	149
31	A chiral HPLC-UV method for the quantification of dibenz[b,f]azepine-5-carboxamide derivatives in mouse plasma and brain tissue: Eslicarbazepine acetate, carbamazepine and main metabolites. <i>Journal of Separation Science</i> , 2011, 34, 1391-1401.	1.3	15